Raymond James & Associates Lowers Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Raymond James & Associates lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 353,218 shares of the life sciences company’s stock after selling 28,015 shares during the period. Raymond James & Associates owned about 0.22% of Illumina worth $49,182,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ILMN. Vanguard Group Inc. lifted its position in Illumina by 15.0% during the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the last quarter. Polen Capital Management LLC lifted its position in Illumina by 0.6% during the third quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock valued at $703,782,000 after acquiring an additional 29,153 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Illumina by 5.5% during the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock valued at $550,212,000 after acquiring an additional 208,267 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Illumina by 6.6% during the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Illumina by 1.9% during the first quarter. Geode Capital Management LLC now owns 2,928,326 shares of the life sciences company’s stock valued at $679,269,000 after acquiring an additional 54,951 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.

Illumina Stock Up 3.6 %

NASDAQ:ILMN opened at $138.68 on Thursday. The firm has a market capitalization of $22.04 billion, a P/E ratio of -18.89 and a beta of 1.19. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $233.42. The company’s fifty day moving average price is $138.29 and its 200-day moving average price is $129.31. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm posted $0.14 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Illumina in a research report on Wednesday, December 13th. They set an “outperform” rating and a $175.00 target price for the company. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research note on Thursday, January 4th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, February 14th. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $166.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.